• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sonnet BioTherapeutics, Inc.

Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
July 22, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
July 21, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
June 09, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
June 02, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
May 10, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
April 13, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
April 08, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
March 16, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting
February 09, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
February 08, 2022
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
December 17, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
August 30, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
August 19, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
August 16, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Intellectual Property
Tickers SONN
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting
June 14, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
June 08, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Intellectual Property
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
May 17, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
May 10, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
May 03, 2021
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap